Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease

Mov Disord. 2017 Nov;32(11):1566-1573. doi: 10.1002/mds.27101. Epub 2017 Jul 24.

Abstract

Background: Dopamine replacement therapy in PD has been associated with both behavioral addictions and dopamine addiction.

Objectives: To investigate potential association between l-dopa induced neuropsychiatric fluctuations and addictions in PD.

Methods: A cohort of 102 patients with PD suffering from motor complications of l-dopa treatment was prospectively analyzed. We evaluated dopamine addiction, behavioral addictions, and neuropsychiatric fluctuations using the Ardouin scale of behavior in PD.

Results: Patients with (n = 51) or without (n = 51) neuropsychiatric fluctuations did not differ in age, disease duration, medication, or UPDRS III motor score during on and off drug condition. Patients with neuropsychiatric fluctuations had a higher H & Y stage in off-drug condition. A multivariate model showed that dopamine addiction (odds ratio: 8.9; P = 0.02) and behavioral addictions (odds ratio: 3.76; P = 0.033) were more frequent in the presence of neuropsychiatric fluctuations. Behavioral addictions and dopamine addiction were more frequent in the presence than in the absence of on-drug euphoria (46% vs. 13.9%; P < 0.001 and 27% vs 6.2 %; P = 0.003), while conversely, no association emerged between dopamine or behavioral addictions and presence of off-drug dysphoria. Patients with neuropsychiatric fluctuations had a poorer quality of life and a more frequent history of anxiety disorder.

Conclusions: The psychostimulant effects of dopamine treatment during on-drug euphoria, rather than avoidance of off-drug dysphoria, appear to drive both behavioral addictions and abuse of medication. © 2017 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; addictions; dopamine dysregulation syndrome; impulsive control disorders; nonmotor fluctuations.

MeSH terms

  • Aged
  • Behavior, Addictive / chemically induced
  • Behavior, Addictive / physiopathology*
  • Central Nervous System Stimulants / adverse effects*
  • Depressive Disorder / physiopathology*
  • Dopamine Agents / adverse effects*
  • Dyskinesia, Drug-Induced / physiopathology
  • Euphoria / drug effects*
  • Female
  • Humans
  • Levodopa / adverse effects*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*
  • Prospective Studies
  • Substance-Related Disorders / physiopathology*

Substances

  • Central Nervous System Stimulants
  • Dopamine Agents
  • Levodopa